SUPERBUGS AND RECENT CONTROLLING APPROACHES: A MINI REVIEW
DOI:
https://doi.org/10.26873/SVR-1440-2021Keywords:
antibiotic resistance, extended spectrum ꞵ-lactamase, horizontal transfer, herapeutic approaches, nanoparticles, bacteriophage, antimicrobial peptides, gene therapyAbstract
Antimicrobial resistance (AMR) is a growing threat to human and animal health, reducing the ability to treat bacterial infections and consequently the risk of morbidity and mortality caused by resistant bacteria. The World Health Organization (WHO) has predicted 10 million deaths by 2050 due to infectious diseases. A considerable increase in the number of pathogens harbor multidrug resistance genes, seemed to be arising from the extensive use of antimicrobial agents for medical issues particularly in food-producing animals, along with the many pathways of their release into the environment. The emergence of multidrug-resistant (MDR) microorganisms has threatened the longstanding use of antibiotics, which were globally used to save millions of lives. The evolution and spread of AMR have a great adverse impact on human beings. Naturally, bacteria have the genetic ability to acquire and spread resistance to therapeutic agents. Therefore, the major challenge has been to limit the extensive and the inappropriate overuse of antibiotics, in addition to finding new drugs either from synthetic or natural origin to counter microbial resistance by acting on the specific target responsible for MDR. To overcome the crisis of antimicrobial drug resistance, WHO has issued several guidelines on the use of antimicrobial agents, such as preserving antibiotics that are important for human health and preventing their usage in agriculture. Several therapeutic approaches like vaccines, antimicrobial peptides, bacteriophages, and nanotechnology, along with phytochemicals and herbal medicines, are applied in vitro and in vivo experiments and are supposed to be suitable candidates for antimicrobials to combat the rapidly evolving AMR. In this review, we will discuss the causes of this resistance, types, its spread between ecosystems, super-resistance associated with superbugs like E. coli, and the possible therapeutic approaches against MDR pathogens.
References
● 1. Singer AC, Shaw H, Rhodes V, et al. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Micro-biol 2016; 7: 1728.
● 2. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations 2016:4.
● 3. Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on met-agenomics analyses of urban sewage. Nat Commun 2019; 10: 1124.
● 4. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Na-ture reviews. Microbiology 2010; 8: 260–71.
● 5. Martinez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 2008; 321: 365–7.
● 6. Davies J. Where have All the Antibiotics Gone? Can J Infect Dis Med Microbiol 2006; 17: 287–90.
● 7. D'Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature 2011; 477: 457–61.
● 8. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74: 417–33.
● 9. Tacconelli E, Carrara E, Savoldi A, et al. Dis-covery research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18: 318–27.
● 10. Yong D, Toleman MA, Giske CG, et al. Char-acterization of a new metallo-beta-lactamase gene bla(NDM-1) and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-–54.
● 11. Elmonir W, Abd El-Aziz NK, Tartor YH, et al. Emergence of Colistin and Carbapenem Resistance in Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae Isolated from Chickens and Hu-mans in Egypt. Biology 2021; 10: 373.
● 12. Elgresly IMI, Elfeil WMK, El-Tarabili RM, et al. Virulence-Determinants and Antibiotic Resistance Pattern of Salmonella Species Isolated from Fancy Pigeons in Port-Said Governorate, Egypt. Zagazig Vet J 2021; 49: 42–55.
● 13. Ibrahim MME, Bahout AAA, Ayoub MA, et al. Chemical and microbiological evaluation of raw buf-falo milk locally produced in sharkia governorate. Zagazig Vet J 2019; 47: 352–63.
● 14. Samaha-Kfoury JN, Araj GF. Recent develop-ments in beta lactamases and extended spectrum beta lactamases. BMJ 2003; 327: 1209–13.
● 15. Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 2007; 5: 175.
● 16. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064–73.
● 17. Jensen LB, Frimodt-Moller N, Aarestrup FM. Presence of erm gene classes in gram-positive bacte-ria of animal and human origin in Denmark. FEMS Microbiol Lett 1999; 170: 151–8.
● 18. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr 2016; 4: 10.
● 19. Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev 2005; 57: 1451–70.
● 20. Caniça M, Manageiro V, Jones-Dias D, et al. Current perspectives on the dynamics of antibiotic resistance in different reservoirs. Res Microbiol 2015; 166: 594–600.
● 21. Abd El-Aziz NK, Ammar AM, Hamdy MM, et al. First report of aacC5-aadA7Δ4 gene cassette array and phage tail tape measure protein on class 1 in-tegrons of Campylobacter species isolated from ani-mal and human sources in Egypt. Animals 2020; 10: 2067.
● 22. Singh V. Salmonella serovars and their host specificity. J Vet Sci Anim Husb 2013; 1: 301.
● 23. Van Hoek AH, Mevius D, Guerra B, et al. Acquired antibiotic resistance genes: an overview. Front Microbiol 2011; 2: 203.
● 24. Rehman MU, Zhang H, Iqbal MK, et al. Anti-biotic resistance serogroups virulence genes and phylogenetic groups of Escherichia coli isolated from yaks with diarrhea in Qinghai plateau China. Gut Pathog. 2017a; 9: 24.
● 25. Tartor YH, El-Naenaeey EY. RT-PCR detec-tion of exotoxin genes expression in multidrug re-sistant Pseudomonas aeruginosa. Cell Mol Biol (Noisy-le-grand). 2016; 62: 56–62.
● 26. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2: 123–140.
● 27. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289: 321–31.
● 28. Bush K, Jacoby GA, Medeiros AA. A function-al classification scheme for betalactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33.
● 29. Datta N, Kontomichalou P. Penicillinase syn-thesis controlled by infectious R factors in Entero-bacteriaceae. Nature 1965; 208: 239–41.
● 30. Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557–84.
● 31. Evans BA, Amyes SGB. OXA β-lactamases. Clin. Microbiol. Rev. 2014; 27: 241–63.
● 32. Gazouli M, Tzelepi E, Markogiannakis A, Legakis NJ, Tzouvelekis LS. Two novel plasmid-mediated cefotaxime-hydrolyzing Î2-lactamases (CTX-M-5 and CTX-M-6) from Salmonella Typhi-murium FEMS Microbiol. Lett 1998; 165: 289–93.
● 33. Matthew M. Plasmid-mediated beta-lactamases of Gram-negative bacteria: properties and distribu-tion. J Antimicrob Chemother 1979; 5: 349–58.
● 34. Jacoby GA. AmpC beta-lactamases. Clin Mi-crobiol Rev 2009; 22: 161–82.
● 35. Schmidtke AJ, Hanson ND. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance. J Antimicrob Chemother 2006; 50: 2030–7.
● 36. Jena J, Sahoo RK, Debata NK, et al. Prevalence of TEM SHV and CTX-M genes of extended-spectrum β-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. 3 Bio-tech 2017; 7: 244.
● 37. Rudramurthy GR, Swamy MK, Sinniah UR, et al. Nanoparticles: alternatives against drug-resistant pathogenic microbes. Molecules 2016; 21: 836.
● 38. Hussein MMA, Gamal F, Arisha AH. Some biological and biomedical effects of nanoparticles. Zagazig Vet J 2020; 48: 433–47.
● 39. Hemeg HA. Nanomaterials for alternative anti-bacterial therapy. Int J Nanomed 2017; 12: 8211–25.
● 40. Daghighi S, Sjollema J, Van der Mei HC, et al. Infection resistance of degradable versus non-degradable biomaterials: an assessment of the poten-tial mechanisms. Biomaterials 2013; 34: 8013–17.
● 41. Happy Agarwal, Menon S, Venkat Kumar S, Rajesh Kumar S. Mechanistic study on antibacterial action of zinc oxide nanoparticles synthesized using green route. Chem Biol Interact 2018; 286: 60–70.
● 42. Venkatesh N, Harish Kumar K, Bhowmik H, et al. Metallic nanoparticle: a review. Biomed J Sci Tech Res 2018; 4: 3765–75.
● 43. Hoseinzadeh E, Makhdoumi P, Taha P, et al. A review on nano-antimicrobials: metal nanoparticles methods and mechanisms. Curr Drug Metabol 2017; 18: 120-–8.
● 44. Beyth N, Houri-Haddad Y, Domb A, Khan W, et al. Alternative antimicrobial approach: nano-antimicrobial materials. Evid Based Complementary Altern Med 2015; Article ID 246012, 16 pages.
● 45. Abd El-Aziz NK, Ammar AM, El-Naenaeey EYM, et al. Antimicrobial and antibiofilm potentials of cinnamon oil and silver nanoparticles against Strep-tococcus agalactiae isolated from bovine mastitis: New avenues for countering resistance. BMC Vet Res 2021; 17: 1–14.
● 46. Qayyum S, Oves M, Khan AU. Obliteration of bacterial growth and biofilm through ROS generation by facilely synthesized green silver nanoparticles. PLoS ONE 2017; 12: 0181363.
● 47. Wypij M, Swiecimska M, Czarnecka J, et al. Antimicrobial and cytotoxic activity of silver nanopar-ticles synthesized from two haloalkaliphilic actinobac-terial strains alone and in combination with antibiot-ics. J Appl Microbiol 2018; 124: 1411–24.
● 48. Gharieb RMA, Saad MF, Mohamed AS, et al. Characterization of two novel lytic bacteriophages for reducing biofilms of zoonotic multidrug-resistant Staphylococcus aureus and controlling their growth in milk. LWT 2020, 124: 109145.
● 49. Sabouri S, Sepehrizadeh Z, Amirpour-Rostami S, et al. A minireview on the in vitro and in vivo exper-iments with anti-Escherichia coli O157: H7 phages as potential biocontrol and phage therapy agents. Int J Food Microbiol 2017; 243: 52–7.
● 50. Latz S, Wahida A, Arif A, et al. Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria. J Basic Microbiol 2016; 56: 1117–23.
● 51. Domingo-Calap P, Delgado-Martínez J. Bacte-riophages: protagonists of a post-antibiotic era. Anti-biotics 2018; 7: 66.
● 52. Pirnay JP, Verbeken G, Ceyssens PJ, et al. The magistral phage. Viruses 2018; 10: 64.
● 53. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013; 8: 769–83.
● 54. Rohde C, Resch G, Pirnay JP, et al. Expert opinion on three phage therapy related topics: bacte-rial phage resistance phage training and prophages in bacterial production strains. Viruses 2018; 10:178.
● 55. Chen J, Novick RP. Phage-mediated intergener-ic transfer of toxin genes. Science 2009; 323: 139–41.
● 56. Mcnair K, Bailey BA, Edwards RA. PHACTS a computational approach to classifying the lifestyle of phages. Bioinformatics 2012; 28: 614–8.
● 57. Fadlallah A, Chelala E, Legeais JM. Corneal infection therapy with topical bacteriophage admin-istration. Open Ophthalmol J 2015; 9: 167–8.
● 58. Fish R, Kutter E, Wheat G, et al. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 2016; 25: S27–33.
● 59. Ujmajuridze A, Chanishvili N, Goderdzishvili M, et al. Adapted bacteriophages for treating urinary tract infections. Front Microbiol 2018; 9:1832.
● 60. Chaudhry WN, Concepcion-Acevedo J, Park T, et al. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE 2017; 12: e0168615.
● 61. Rios AC, Moutinho CG, Pinto FC et al. Alter-natives to overcoming bacterial resistances: state-of-the-art. Microbiol Res 2016; 191: 51–80.
● 62. Lin Y, Chang RYK, Britton WJ, et al. Synergy of nebulized phage PEV20 and ciprofloxacin combi-nation against Pseudomonas aeruginosa. Int J Pharm 2018; 551: 158–65.
● 63. Wang G, Li X, Zasloff M. “A database view of naturally occurring antimicrobial peptides: nomencla-ture classification and amino acid sequence analysis” in Antimicrobial Peptides: Discovery Design and Novel Therapeutic Strategies. (Oxfordshire: CABI Publishing) 2010: 1–21.
● 64. Cho J, sok Hwang I, Choi H, et al. The novel biological action of antimicrobial peptides via apopto-sis induction. J Microbiol Biotechnol 2012; 22: 1457–66.
● 65. Berglund NA, Piggot TJ, Jefferies D, et al. Interaction of the antimicrobial peptide polymyxin B1 with both membranes of E coli: a molecular dynamics study. PLoS Comput Biol 2015; 11: e1004180.
● 66. Devocelle M. Targeted antimicrobial peptides. Front Immunol 2012; 3: 309.
● 67. Pfalzgraff A, Brandenburg K, Weindl G. Anti-microbial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharma-col 2018; 9: 281.
● 68. Téllez GA, Zapata JA, Toro LJ, et al. Identifica-tion characterization immunolocalization and biologi-cal activity of lucilin peptide. Acta Trop 2018; 185: 318–26.
● 69. Du H, Puri S, McCall A, et al. Human salivary protein histatin 5 has potent bactericidal activity against ESKAPE pathogens. Front Cell Infect Mi-crobiol 2017; 7: 41.
● 70. Lin Q, Deslouches B, Montelaro RC, et al. Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. Int J Antimicrob Agents 2018; 52: 667–72.
● 71. Gaglione R, Dell’Olmo E, Bosso A, et al. Nov-el human bioactive peptides identified in Apolipopro-tein B: evaluation of their therapeutic potential. Bio-chem Pharmacol 2017; 130: 34–50.
● 72. Björn C, Mahlapuu M, Mattsby-Baltzer I, et al. Antiinfective efficacy of the lactoferrin-derived anti-microbial peptide HLR1r. Peptides 2016; 81: 21–8.
● 73. Al Akeel R, Mateen A, Syed R, et al. Alanine rich peptide from Populus trichocarpa inhibit growth of Staphylococcus aureus via targetting its extracellular domain of Sensor Histidine Kinase YycGex protein. Microb Pathog 2018; 121: 115–22.
● 74. Xie J, Li Y, Li J, et al. Potent effects of amino acid scanned antimicrobial peptide Feleucin-K3 ana-logs against both multidrug-resistant strains and bio-films of Pseudomonas aeruginosa. Amino Acids 2018; 50: 1471–83.
● 75. Rishi NP, Vashist T, Sharma A, et al. Efficacy of designer K11 antimicrobial peptide (a hybrid of melittin cecropin A1 and magainin 2) against Acineto-bacter baumannii infected wounds. Pathog Dis 2018; 76: fty072.
● 76. Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of ther-apeutic agents. Front Cell Infect Microbiol 2016; 6:194.
● 77. Reinhardt A, Neundorf I. Design and applica-tion of antimicrobial peptide conjugates. Int J Mol Sci 2016; 17: E701.
● 78. Pletzer D, Mansour SC, Hancock REW. Syner-gy between conventional antibiotics and anti-biofilm peptides in a murine sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. PLoS Pathog 2018; 14:e1007084.
● 79. Chaudhari AA, Ashmore D, Nath S, et al. A novel covalent approach to bio-conjugate silver coat-ed single walled carbon nanotubes with antimicrobial peptide. J Nanobiotechnol 2016; 14: 58.
● 80. Otvos L, Ostorhazi E, Szabo D, et al. Synergy between proline-rich antimicrobial peptides and small molecule antibiotics against selected gram-negative pathogens in vitro and in vivo. Front Chem 2018; 6: 309.
● 81. Wang S, Yan C, Zhang X, et al. Antimicrobial peptide modification enhances the gene delivery and bactericidal efficiency of gold nanoparticles for ac-celerating diabetic wound healing. Biomater Sci 2018; 6: 2757–72.
● 82. Yang MY, Chang KC, Chen LY, et al. Blue light irradiation triggers the antimicrobial potential of ZnO nanoparticles on drug-resistant Acinetobacter baumannii. J Photochem Photobiol B 2018; 180: 235–42.
● 83. Cieplik F, Deng D, Crielaard W, et al. Antimi-crobial photodynamic therapy – what we know and what we don’t. Crit Rev Microbiol 2018; 44: 571–89.
● 84. Ullah A, Zhang Y, Iqbal Z, et al. Household light source for potent photo-dynamic antimicrobial effect and wound healing in an infective animal mod-el. Biomed Opt Express 2018; 9: 1006–19.
● 85. Halstead FD, Thwaite JE, Burt R, et al. Anti-bacterial activity of blue light against nosocomial wound pathogens growing planktonically and as ma-ture biofilms. Appl Environ Microbiol 2016; 82: 4006–16.
● 86. Maliszewska I, Kałas W, Wysokiéska E, et al. Enhancement of photo-bactericidal effect of tetrasul-fonated hydroxyaluminum phthalocyanine on Pseudo-monas aeruginosa. Lasers Med Sci 2018; 33: 79–88.
● 87. Nour El Din S, El-Tayeb TA, Abou-Aisha K, et al. In vitro and in vivo antimicrobial activity of combined therapy of silver nanoparticles and visible blue light against Pseudomonas aeruginosa. Int J Nano-med 2016; 11: 1749–58.
● 88. Nakonieczna J, Wolnikowska K, Ogonowska P, et al. Rose bengal-mediated photoinactivation of mul-tidrug resistant Pseudomonas aeruginosa is enhanced in the presence of antimicrobial peptides. Front Micro-biol 2018; 9: 1949.
● 89. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of vi typhoid vaccine in India. N Engl J Med 2009; 361: 335–44.
● 90. Zerva I, Katsoni E, Simitzi C, et al. Laser mi-cro-structured Si scaffold-implantable vaccines against Salmonella Typhimurium. Vaccine 2019; 37:2249–57.
● 91. Battesti A, Majdalani N, Gottesman S. The RpoS-mediated general stress response in Escherichia coli. Annu Rev Microbiol 2011; 65:189–213.
● 92. Hagens S, Loessner M. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharmaceut Biotechnol 2010; 11:58–68.
● 93. Zwir I, Shin D, Kato A, et al. Dissecting the PhoP regulatory network of Escherichia coli and Salmo-nella enterica. Proc Natl Acad Sci USA 2005; 102: 2862–7.
● 94. Soncini FC, Véscovi EG, Solomon F, et al. Molecular basis of the magnesium deprivation re-sponse in Salmonella typhimurium: identification of PhoP-regu-lated genes. J Bacteriol 1996; 178:5092–9.
● 95. Castelli ME, García Véscovi E, Soncini FC. The phosphatase activity is the target for Mg 2+ regulation of the sensor protein PhoQ in Salmonella. J Biol Chem 2000; 275: 22948–54.
● 96. Kox LFF. A small protein that mediates the activation of a two-component system by another two-component system. EMBO J 2000; 19: 1861–72.
● 97. Perez JC, Shin D, Zwir I, et al. Evolution of a bacterial regulon controlling virulence and mg2+ homeostasis. PLoS Genet 2009; 5:e1000428.
● 98. Walthers D, Carroll RK, Navarre WW, et al. The response regulator SsrB activates expression of diverse Salmonella pathogenicity island 2 promoters and counters silencing by the nucleoid-associated protein H-NS. Mol Microbiol 2007; 65: 477–93.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Mervat Ibrahim, Esmat Elsaied, Salah Abd el aal, Mohamed Bayoumi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
